Mission
ACCELERATING THE DEVELOPMENT OF ADVANCED DIAGNOSTIC TOOLS AND EFFECTIVE TREATMENTS FOR SYSTEMIC AMYLOIDOSIS THROUGH COLLABORATION AND INNOVATION.
Public Charity
AMYLOIDOSIS RESEARCH CONSORTIUM INC
AMYLOIDOSIS RESEARCH CONSORTIUM INC, of NEWTON, MA, is a Public Charity tracked in Imperigo's IRS 990 database. The 2024 filing shows $3.4M in revenue, $3.0M in expenses, $4.7M in total assets. 21 publicly reported grants to this organization, totaling roughly $477K, appear in IRS filings.
EIN: 472589708
NEWTON, MA
Specifically Named Diseases Research
NTEE: H80
Latest filing: 2024
Total Revenue$3.4M
Total Expenses$3.0M
Total Assets$4.7M
Grant Records21
Funding Total$477K
Filing Years2019–2024
Sample Grants Received
PROGRAM SPECIFIC SUPPORT
$50,000
FOR RECIPIENT'S EXEMPT PURPOSE
$8,000
For grant recipient's exempt purposes
$7,700
JCF GRANTS FROM DAFS AND ENDOWMENTS
$6,500
PROGRAM SPECIFIC SUPPORT
$25,000
Showing up to 5 of 21 total records — full history available with membership.
Officers & Directors
BOARD MEMBER
Ashutosh Wechalekar
BOARD MEMBER
Dr Raymond Comenzo
PRESIDENT/CEO & CLERK
Isabelle Lousada
TREASURER
Jason Shore
BOARD MEMBER
Laura Strickland
BOARD MEMBER
Mark Guidinger
Officer compensation and complete director data available with membership.
Top Grant Purposes
Financial Trends
| Year | Revenue | Expenses | Assets |
|---|---|---|---|
| 2024 | $3.4M | $3.0M | $4.7M |
| 2023 | $2.9M | $2.4M | $3.0M |
| 2022 | $2.3M | $2.1M | $2.5M |
| 2020 | $2.1M | $1.2M | $2.3M |
| 2019 | $1.7M | $1.3M | $1.4M |
Between 2019 and 2024, reported annual revenue grew from $1.7M to $3.4M (+98%), with total assets most recently reported at $4.7M.
Interactive year-over-year charts and full filing details available with membership.